CompletedPHASE1, PHASE2NCT01325181
Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy
Studying Central serous chorioretinopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jang Won Heo
- Principal Investigator
- Jang Won Heo, ProfessorSeoul National University Hospital
- Intervention
- Verteporfin(drug)
- Enrollment
- 34 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2009 – 2012
Study locations (1)
- • Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Gyeonggi-do, South Korea
Collaborators
Novartis Korea Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01325181 on ClinicalTrials.govOther trials for Central serous chorioretinopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06527326the Study of the Association Between the Gut Microbiota and Central Serous ChorioretinopathySecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGNCT06346405Central Serous Chorioretinopathy and Micropulse Laser TreatmentFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNANCT05570591Subthreshold Nanosecond Laser for Non-resolving Central Serous ChorioretinopathyNova Eye Medical Pty Ltd.
- RECRUITINGNCT05589974Choroidal Blood Flow in Acute and Chronic Central Serous ChorioretinopathyHelse Stavanger HF